Keenan Gentry - Wesana Health VP Devel
| WSNAF Stock | USD 0 0 28.33% |
Insider
Keenan Gentry is VP Devel of Wesana Health Holdings
| Phone | 773 236 7972 |
| Web | https://www.wesanahealth.com |
Wesana Health Management Efficiency
The company has return on total asset (ROA) of (0.4236) % which means that it has lost $0.4236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7162) %, meaning that it generated substantial loss on money invested by shareholders. Wesana Health's management efficiency ratios could be used to measure how well Wesana Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | INSIDER Age | ||
| Theis MD | GH Research PLC | 48 | |
| Susan Prohaska | Jasper Therapeutics | N/A | |
| William Lis | Jasper Therapeutics | 60 | |
| Carol Zoltowski | Jasper Therapeutics | 74 | |
| Florian M | GH Research PLC | 55 | |
| Magnus Halle | GH Research PLC | 27 | |
| Jeet MBA | Jasper Therapeutics | N/A | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Kevin MD | Jasper Therapeutics | 53 | |
| Julie ACA | GH Research PLC | 38 | |
Management Performance
| Return On Equity | -1.72 | |||
| Return On Asset | -0.42 |
Wesana Health Holdings Leadership Team
Elected by the shareholders, the Wesana Health's board of directors comprises two types of representatives: Wesana Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wesana. The board's role is to monitor Wesana Health's management team and ensure that shareholders' interests are well served. Wesana Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wesana Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Carcillo, CEO CoFounder | ||
| Jeffrey Jewell, VP Affairs | ||
| Zed Wang, CFO Sec | ||
| Mark Wingertzahn, Chief Officer | ||
| Chad Bronstein, CoFounder | ||
| Keenan Gentry, VP Devel | ||
| Izzy Forman, VP Communications |
Wesana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Wesana Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (49.56) % | |||
| Current Valuation | (851.39 K) | |||
| Shares Outstanding | 20.49 M | |||
| Shares Owned By Insiders | 4.64 % | |||
| Shares Owned By Institutions | 13.77 % | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 2.53 X | |||
| Revenue | 267.2 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Wesana Pink Sheet
Wesana Health financial ratios help investors to determine whether Wesana Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wesana with respect to the benefits of owning Wesana Health security.